Physician
Spinal Technology and Pain Center INC
Spinal Technology and Pain Center INC was paid $23.87M by Medicaid between Jan 2018 and Apr 2022, across 43 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 14% of everything it billed.
33Billing provider infoSPINAL TECHNOLOGY AND PAIN CENTER INC
LANCASTER, OH 43130
LANCASTER, OH 43130
33aNPI1346363306assigned 04/06/2007
33bProvider typeAddiction Medicine (Family Medicine) Physician
28Total paid$23.87M
24GClaims1,315,001
24DCodes billed43
24AFirst – last monthJan 2018 – Apr 2022
Compared with peers
Next to other Addiction Medicine (Family Medicine) Physician providers in Ohio
Rank by total paid#1 of 29
Median peer was paid$192K
This provider vs. median124×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 190,074 | $2.79M | |
| 2019 | 537,339 | $8.55M | |
| 2020 | 494,963 | $8.16M | |
| 2021 | 92,010 | $4.35M | |
| 2022 | 615 | $13K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 14% | 69,243 | 35,581 | $3.40M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 68,362 | 35,991 | $2.81M |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 7.8% | 68,577 | 37,981 | $1.86M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 7.6% | 12,645 | 7,948 | $1.81M |
| 82075 | 6.5% | 83,435 | 41,798 | $1.55M | |
| 80346 | 4.3% | 47,026 | 25,427 | $1.03M | |
| 80361 | 3.7% | 48,227 | 26,024 | $893K | |
| 80363 | 3.2% | 39,957 | 22,217 | $757K | |
| 83992 | 2.9% | 46,985 | 25,391 | $698K | |
| 80365 | 2.1% | 47,188 | 25,534 | $493K | |
| 80372 | 2.0% | 46,599 | 25,238 | $489K | |
| 80373 | 2.0% | 46,497 | 25,168 | $487K |
31 more codes
| 80366 | 2.0% | 46,304 | $486K | |
| 80355 | 2.0% | 46,325 | $486K | |
| 80348 | 2.0% | 45,778 | $480K | |
| 80354 | 2.0% | 45,442 | $476K | |
| 80356 | 2.0% | 45,501 | $476K | |
| 80358 | 2.0% | 45,424 | $475K | |
| 80349 | 2.0% | 45,313 | $474K | |
| 80345 | 2.0% | 45,238 | $473K | |
| 80360 | 2.0% | 45,245 | $473K | |
| 80359 | 2.0% | 45,243 | $473K | |
| 80353 | 2.0% | 45,244 | $473K | |
| 80336 | 1.7% | 38,975 | $411K | |
| 80370 | 1.7% | 38,982 | $411K | |
| 80324 | 1.7% | 38,428 | $405K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.1% | 14,200 | $257K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 11,462 | $157K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,958 | $141K |
| 80364 | <1% | 7,352 | $134K | |
| 80335 | <1% | 7,328 | $75K | |
| 80325 | <1% | 6,922 | $70K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,417 | $60K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,754 | $56K |
| 80305 | <1% | 5,436 | $49K | |
| 81025 | <1% | 8,428 | $49K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 319 | $29K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 281 | $25K |
| Q3014 | Telehealth originating site facility fee | <1% | 3,472 | $8K |
| 90836 | <1% | 168 | $7K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 154 | $6K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 131 | $5K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 36 | $1K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMASONE, ROBERT (PRESIDENT)